Figures & data
Figure 1 (A) The synthesis of poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG1k-PDLLA10k) and (B) proton nuclear magnetic resonance spectra of mPEG1k-PDLLA in CDCl3 at 25°C. Characteristic peaks of PEG and PDLLA were located at about 3.6 ppm and 5.1–5.3 ppm (CH) and 1.5–1.6 ppm (CH3), respectively.
Abbreviation: Peg1k-PDLLA10k, polyethylene glycol-polylactide.
![Figure 1 (A) The synthesis of poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG1k-PDLLA10k) and (B) proton nuclear magnetic resonance spectra of mPEG1k-PDLLA in CDCl3 at 25°C. Characteristic peaks of PEG and PDLLA were located at about 3.6 ppm and 5.1–5.3 ppm (CH) and 1.5–1.6 ppm (CH3), respectively.Abbreviation: Peg1k-PDLLA10k, polyethylene glycol-polylactide.](/cms/asset/58708680-9825-4c3f-87c6-c3856a77c116/dijn_a_54142_f0001_b.jpg)
Figure 2 Synthesis of polymeric nanovesicles.
Abbreviations: DOX, doxorubicin; PDLLA, poly(D,L-lactic acid); PEG, poly(ethylene glycol); THF, tetrahydrofuran.
![Figure 2 Synthesis of polymeric nanovesicles.Abbreviations: DOX, doxorubicin; PDLLA, poly(D,L-lactic acid); PEG, poly(ethylene glycol); THF, tetrahydrofuran.](/cms/asset/9d2e144a-ab87-4d53-a06f-9780eaa4f37e/dijn_a_54142_f0002_c.jpg)
Figure 3 Transmission electron microscope photos of poly(ethylene glycol)-block-poly(D,L-lactic acid) vesicles. The structure of synthesized nanovesicles was clear, which was hollow and spherical. Particle size distribution was relatively homogeneous.
![Figure 3 Transmission electron microscope photos of poly(ethylene glycol)-block-poly(D,L-lactic acid) vesicles. The structure of synthesized nanovesicles was clear, which was hollow and spherical. Particle size distribution was relatively homogeneous.](/cms/asset/754e577e-a1c8-4a3c-a451-516099dacf66/dijn_a_54142_f0003_b.jpg)
Figure 4 Particle sizing distribution of (A) poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-PDLLA) blank vesicle, (B) doxorubicin (DOX)-loaded PEG-PDLLA vesicle, (C) photosensitizer-loaded PEG-PDLLA vesicle, and (D) DOX- and photosensitizer-loaded PEG-PDLLA vesicle.
![Figure 4 Particle sizing distribution of (A) poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-PDLLA) blank vesicle, (B) doxorubicin (DOX)-loaded PEG-PDLLA vesicle, (C) photosensitizer-loaded PEG-PDLLA vesicle, and (D) DOX- and photosensitizer-loaded PEG-PDLLA vesicle.](/cms/asset/4e42a872-7ec7-4fb3-8f86-581a599dfff6/dijn_a_54142_f0004_b.jpg)
Figure 5 The toxicity of empty nanovesicles poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-PDLLA) on HepG2.
![Figure 5 The toxicity of empty nanovesicles poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-PDLLA) on HepG2.](/cms/asset/851ffcd9-69f8-48b8-bad5-649e1849bcf6/dijn_a_54142_f0005_b.jpg)
Figure 6 The toxicity of three groups of drug-loading nanoparticle vesicles.
Abbreviations: DOX, doxorubicin; HMME, hematoporphyrin monomethyl ether; PDLLA, poly(D,L-lactic acid); PEG, poly(ethylene glycol).
![Figure 6 The toxicity of three groups of drug-loading nanoparticle vesicles.Abbreviations: DOX, doxorubicin; HMME, hematoporphyrin monomethyl ether; PDLLA, poly(D,L-lactic acid); PEG, poly(ethylene glycol).](/cms/asset/a08dbc4c-d366-49d1-bee8-b101a73dec98/dijn_a_54142_f0006_c.jpg)
Figure 7 Reactive oxygen species levels in HepG2 cells following treatment with drug-loaded nanovesicles.
Abbreviations: DOX, doxorubicin; HMME, hematoporphyrin monomethyl ether; PDLLA, poly(D,L-lactic acid); PEG, poly(ethylene glycol).
![Figure 7 Reactive oxygen species levels in HepG2 cells following treatment with drug-loaded nanovesicles.Abbreviations: DOX, doxorubicin; HMME, hematoporphyrin monomethyl ether; PDLLA, poly(D,L-lactic acid); PEG, poly(ethylene glycol).](/cms/asset/d8669901-7c21-471b-bc91-87403b530535/dijn_a_54142_f0007_c.jpg)
Figure 8 Mitochondrial membrane potential depolarization in HepG2 cells following treatment with drug-loaded nanovesicles.
Abbreviations: DOX, doxorubicin; HMME, hematoporphyrin monomethyl ether; PDLLA, poly(D,L-lactic acid); PEG, poly(ethylene glycol); FITC-A, fluorescein isothiocyanate apoptosis; PI-A, propidine iodide apoptosis; Q, quadrant.
![Figure 8 Mitochondrial membrane potential depolarization in HepG2 cells following treatment with drug-loaded nanovesicles.Abbreviations: DOX, doxorubicin; HMME, hematoporphyrin monomethyl ether; PDLLA, poly(D,L-lactic acid); PEG, poly(ethylene glycol); FITC-A, fluorescein isothiocyanate apoptosis; PI-A, propidine iodide apoptosis; Q, quadrant.](/cms/asset/9fe8415b-ae78-4900-822e-293c2c5742af/dijn_a_54142_f0008_c.jpg)
Figure 9 The apoptosis-inducing rate test result of drug-loaded nanovesicles.
Abbreviations: DOX, doxorubicin; HMME, hematoporphyrin monomethyl ether; PDLLA, poly(D,L-lactic acid); PEG, poly(ethylene glycol); FITC-A, fluorescein isothiocyanate apoptosis; PI-A, propidine iodide apoptosis; Q, quadrant.
![Figure 9 The apoptosis-inducing rate test result of drug-loaded nanovesicles.Abbreviations: DOX, doxorubicin; HMME, hematoporphyrin monomethyl ether; PDLLA, poly(D,L-lactic acid); PEG, poly(ethylene glycol); FITC-A, fluorescein isothiocyanate apoptosis; PI-A, propidine iodide apoptosis; Q, quadrant.](/cms/asset/4d7785f3-0819-4bcf-8ce1-11e688946a8b/dijn_a_54142_f0009_c.jpg)